Allurion Presents Promising Results from Large-Scale Study
Allurion Technologies, Inc. (NYSE: ALUR), a company passionate about addressing obesity, has recently disclosed impressive outcomes during the Obesity Society’s Annual Conference. During this event, they presented two significant abstracts that shed light on the effectiveness of the Allurion Program.
Insights from the Largest Real-World Cohort
The first presentation outlines pivotal data collected from Allurion’s extensive real-world study, which stands as the largest of its kind. This research compiles results from 19,428 patients across 72 countries who participated in the Allurion Program from 2018 to 2023. Utilizing the Allurion Virtual Care Suite, the program provided digital tracking of participants’ results, showcasing an impressive average weight loss of 12.2% within just four months.
Significance of Real-World Data
Dr. Shantanu Gaur, Allurion's Founder and CEO, emphasized the importance of this data. He stated that while various clinical trials have explored intragastric balloons, substantial real-world data has been sparse. The findings from this cohort establish that the Allurion Program consistently enables clinically meaningful weight loss across a diverse range of patients, many of whom have previously struggled with traditional weight management methods.
Revolutionizing Outcomes for GLP-1 Non-Responders
In their second abstract, Allurion examined outcomes from 27 patients who had previously undergone treatment with liraglutide but saw minimal success. Alarmingly, the study showed that 55% of these individuals experienced no weight loss, and 45% achieved less than 5% weight reduction while on GLP-1 therapies. In stark contrast, those who transitioned to the Allurion Program experienced an astonishing average weight loss of 17.6% after just four months.
Implication for Obesity Treatments
Dr. Ram Chuttani, Chief Medical Officer of Allurion, pointed out the alarming trend noted in numerous clinical studies: more than a third of patients typically do not reach a weight loss of over 10% after a year on GLP-1 medications. With the traditionally lengthy timeline needed to assess the effectiveness of these treatments, the immediate and encouraging results observed with the Allurion Program may provide hope for those who haven't experienced success with other methodologies.
About Allurion Technologies
Allurion is dedicated to transforming the landscape of obesity treatment. Their flagship innovation, the Allurion Program, comprises the revolutionary Allurion Gastric Balloon—global first in swallowable, procedure-less intragastric balloons for weight loss. Complementing this is the Allurion Virtual Care Suite, a comprehensive digital platform that integrates essential features such as the Allurion Mobile App for patients, insightful data for healthcare providers, and advanced tools like Coach Iris AI, enhancing patient monitoring and treatment.
Beyond the Allurion Program, the Virtual Care Suite makes these tools accessible to healthcare providers with an aim to customize and manage weight-loss therapies, regardless of the method used. Notably, the Allurion Gastric Balloon is still an investigational device in the United States, signifying innovation in the field of weight management.
Frequently Asked Questions
What is the Allurion Program?
The Allurion Program is an innovative weight loss system that includes the Allurion Gastric Balloon and the Allurion Virtual Care Suite, which provides personalized monitoring and support.
How effective is the Allurion Program?
Recent studies show that patients participating in the Allurion Program experienced an average weight loss of 12.2% over four months, with some achieving as much as 17.6% weight reduction.
Who can benefit from the Allurion Program?
The program is suitable for individuals struggling with weight management, including those who have not achieved desired results using other obesity treatments such as GLP-1 medications.
Are the devices used in the program FDA approved?
The Allurion Gastric Balloon is currently investigational in the United States; however, the program has been positively received in other countries.
What kind of support does the Allurion Virtual Care Suite offer?
The Allurion Virtual Care Suite features a mobile app for patients, data and insights for healthcare providers, and tools for remote monitoring to enhance patient success in weight management.
